Monte Rosa Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2025
Filed with the SEC on May 8, 2025 and accepted by EDGAR at May 8, 2025, 11:14 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-01-01 to 2025-03-31 | $84.9m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Research and development | 3 months2025-01-01 to 2025-03-31 | $32.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-01-01 to 2025-03-31 | $44.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2025-01-01 to 2025-03-31 | $822.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-01-01 to 2025-03-31 | $46.9m | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months2025-01-01 to 2025-03-31 | 82,956,423 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2025-01-01 to 2025-03-31 | −$45.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2025-01-01 to 2025-03-31 | $1.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2025-01-01 to 2025-03-31 | $0 | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2025-03-31 | $78.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-03-31 | $332.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-03-31 | $393.2m | us-gaap:Assets |
| Current liabilities | At period end2025-03-31 | $59.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-03-31 | $118.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-03-31 | $275.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-25-066372. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.